Canadian Journal of Gastroenterology and Hepatology / 2019 / Article / Tab 3

Research Article

Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy

Table 3

Individual efficacy data depending on HCV genotype, hepatic fibrosis, and primary and rescue regimen.

PatientFibrosisGTPrimary regimenResponse to primary reg.Months between therapiesRescue regimenResponse to rescue reg.

143OBV/PTV/r+DSV+RBVREL6LDV/SOF+RBV, 12wksNR
241BOBV/PTV/r+DSV+RBVDSC, 1wk1LDV/SOF+RBV, 12wksSVR
341BOBV/PTV/r+DSV+RBVDSC, 2wks11LDV/SOF, 12wksLFU
441BOBV/PTV/r+DSV+RBVDSC, 3wks11LDV/SOF, 24wksSVR
511BOBV/PTV/r+DSVDSC, 4 wks5LDV/SOF, 12wksSVR
641BOBV/PTV/r+DSV+RBVDSC, 4 wks2LDV/SOF, 24wksSVR
711BOBV/PTV/r+DSVDSC, 1 wk2LDV/SOF, 12wksSVR
841BOBV/PTV/r+DSV+RBVDSC, 2wks17LDV/SOF, 12wksSVR
941BOBV/PTV/r+DSV+RBVDSC, 3wks10LDV/SOF+RBV, 12wksSVR
1041BOBV/PTV/r+DSV+RBVDSC, 4wks9LDV/SOF, 24wksSVR
1131BOBV/PTV/r+DSVNR12LDV/SOF+RBV, 12wksSVR
1211BOBV/PTV/r+DSVDSC, 1 day7LDV/SOF, 8wksSVR
1343SOF+RBVREL3.5SOF+DCV, 12wks →
SOF+RBV, 12wks
SVR
1424SOF+RBVNR6GZR/EBR, 12wksSVR
1543SOF+RBVREL8SOF+DCV+RBV 24wksSVR
1641BLDV/SOF+RBVREL9LDV/SOF+RBV, 24wksNR
1744LDV/SOF+RBVREL8GZR/EBR, 12wksLFU
1834LDV/SOFNR16OBV/PTV/r+RBV, 24wksSVR
1921BLDV/SOFREL16OBV/PTV/r+DSV, 12wksSVR
2004LDV/SOFREL7GZR/EBR+RBV, 16wksSVR
2141BLDV/SOF+RBVNR17LDV/SOF+RBV, 24wksSVR
2241BLDV/SOF+RBVNR14SOF+DCV+RBV 24wksNR
2341BASV+DCVNR4OBV/PTV/r+DSV+RBV, 12wksNR
2444ASV+DCVUKN0OBV/PTV/r+RBV, 24wksSVR
2541BASV+DCVNR12LDV/SOF+RBV, 24wksSVR
2641BSMV+SOF+RBVREL13LDV/SOF+RBV, 24wksSVR
2741BSOF+DCV+RBVNR4GZR/EBR, 12wksSVR
2841BOBV/PTV/r+DSV+RBVDSC, 4wks12LDV/SOF, 24wksSVR
2941BOBV/PTV/r+DSV+RBVREL12LDV/SOF, 24wksSVR
3041BOBV/PTV/r+DSV+RBVREL7LDV/SOF, 24wksSVR
3121BASV+DCVNR18OBV/PTV/r+DSV+RBV, 12wksSVR

GT: genotype; OBV: ombitasvir; PTV: paritaprevir; DSV: dasabuvir; RBV: ribavirin; LDV: ledipasvir; SOF: sofosbuvir; ASV: asunaprevir; DCV: daclatasvir; GZR: grazoprevir; EBR: elbasvir; REL: relapse; DSC: discontinued; NR: nonresponder, UKN: unknown; LFU: lost to follow-up.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.